Skip to main content

2025 IDWeek Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Session Icons

Live Streamed

On Demand

58 Views

H4. HIV: Treatment

Poster Session: HIV: Treatment

(P-389) Switching to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily Maintains Viral Suppression Through Week 48 in the Presence of Archived NNRTI Resistance-Associated Mutations or M184I/V in Proviral DNA

Monday, October 20, 2025

12:15 PM - 1:30 PM US ET

Location: Poster Hall B4-B5

Presenting Author(s)

Tracy L. Diamond, PhD (she/her/hers)

Senior Principal Scientist
Merck & Co., Inc.
Rahway, NJ, United States

Co-Author(s)

AG

Anjana Grandhi, PhD

Merck & Co., Inc.
Rahway, New Jersey, United States
MF

Monica Fuszard, MS

Merck & Co., Inc
Rahway, New Jersey, United States
YX

Yayun Xu, PhD

Merck
Edison, New Jersey, United States
UN

Uche Nwoke, MS

Merck & Co., Inc.
Rahway, New Jersey, United States
YZ

Ying Zhang, PhD

Merck & Co., Inc.
Rahway, New Jersey, United States
SK

Stephanie O. Klopfer, PhD

Merck & Co., Inc.
Rahway, New Jersey, United States
KE

Karen Eves, BS

Merck & Co., Inc.
Rahway, New Jersey, United States
JB

Jaime Benner, BS

Merck & Co., Inc.
Rahway, New Jersey, United States
ML

Mengchun Li, MD

Merck & Co., Inc.
Rahway, New Jersey, United States
WG

Wayne Greaves, MD

Executive Director
Merck Research Labs
Edison, NJ, United States
RL

Rima Lahoulou, n/a

MSD
Puteaux, Haute-Normandie, France
JK

Jason Y. Kim, MD, MSCE

Director, Clinical Research- Infectious Diseases
Merck & Co., Inc.
Kenilworth, NJ, United States
MF

Michelle C. Fox, MD

Merck & Co., Inc.
Rahway, New Jersey, United States
EA

Ernest Asante-Appiah, PhD

Merck & Co,. Inc
Kenilworth, New Jersey, United States